USD
$0.00
(0.00%
)At Close (As of Nov 6, 2025)
$690.24M
Market Cap
-
P/E Ratio
-2.03
EPS
$9.50
52 Week High
$4.55
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $9.5M |
| Total Revenue | $33M |
| Cost Of Revenue | $24M |
| Costof Goods And Services Sold | $24M |
| Operating Income | -$164M |
| Selling General And Administrative | $54M |
| Research And Development | $119M |
| Operating Expenses | $174M |
| Investment Income Net | - |
| Net Interest Income | -$9.1M |
| Interest Income | $4.1M |
| Interest Expense | $13M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $13M |
| Income Before Tax | -$148M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$148M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$135M |
| Ebitda | -$122M |
| Net Income | -$148M |
| Field | Value (USD) |
|---|---|
| Total Assets | $270M |
| Total Current Assets | $124M |
| Cash And Cash Equivalents At Carrying Value | $104M |
| Cash And Short Term Investments | $104M |
| Inventory | $385K |
| Current Net Receivables | $11M |
| Total Non Current Assets | $146M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $821K |
| Intangible Assets Excluding Goodwill | $821K |
| Goodwill | - |
| Investments | - |
| Long Term Investments | $6.7M |
| Short Term Investments | - |
| Other Current Assets | $8.8M |
| Other Non Current Assets | - |
| Total Liabilities | $202M |
| Total Current Liabilities | $61M |
| Current Accounts Payable | $24M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $8.1M |
| Total Non Current Liabilities | $141M |
| Capital Lease Obligations | $12M |
| Long Term Debt | $73M |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $85M |
| Other Current Liabilities | $24M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $68M |
| Treasury Stock | - |
| Retained Earnings | -$702M |
| Common Stock | $3K |
| Common Stock Shares Outstanding | $70M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$104M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $13M |
| Capital Expenditures | $5M |
| Change In Receivables | - |
| Change In Inventory | -$387K |
| Profit Loss | - |
| Cashflow From Investment | $23M |
| Cashflow From Financing | $55M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$148M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $9.5M |
| Total Revenue | $33M |
| Cost Of Revenue | $24M |
| Costof Goods And Services Sold | $24M |
| Operating Income | -$164M |
| Selling General And Administrative | $54M |
| Research And Development | $119M |
| Operating Expenses | $174M |
| Investment Income Net | - |
| Net Interest Income | -$9.1M |
| Interest Income | $4.1M |
| Interest Expense | $13M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $13M |
| Income Before Tax | -$148M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$148M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$135M |
| Ebitda | -$122M |
| Net Income | -$148M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
MeiraGTx Holdings PLC is a clinical-stage gene therapy company headquartered in New York, dedicated to developing groundbreaking treatments for severe genetic disorders. Leveraging cutting-edge gene-editing technologies, the company targets significant unmet medical needs in therapeutic areas such as ophthalmology, neurology, and rare diseases. With a robust and diversified pipeline, MeiraGTx is poised to become a frontrunner in the field of genetic medicine, aiming to transform the landscape of patient care through its innovative therapeutic solutions.